West Pharmaceutical Services (WST) Competitors

West Pharmaceutical Services logo
$417.21 +0.79 (+0.19%)
Closing price 03:59 PM Eastern
Extended Trading
$417.00 -0.20 (-0.05%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

WST vs. CHE, EHC, MDLN, ALC, and SOLV

Should you buy West Pharmaceutical Services stock or one of its competitors? West Pharmaceutical Services's main competitors and comparable companies include Chemed (CHE), Encompass Health (EHC), Medline (MDLN), Alcon (ALC), and Solventum (SOLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does West Pharmaceutical Services compare to Chemed?

West Pharmaceutical Services (NYSE:WST) and Chemed (NYSE:CHE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

West Pharmaceutical Services currently has a consensus target price of $424.67, indicating a potential upside of 2.00%. Chemed has a consensus target price of $603.00, indicating a potential upside of 9.77%. Given Chemed's higher possible upside, analysts plainly believe Chemed is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
Chemed
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Chemed has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

In the previous week, West Pharmaceutical Services had 4 more articles in the media than Chemed. MarketBeat recorded 10 mentions for West Pharmaceutical Services and 6 mentions for Chemed. West Pharmaceutical Services' average media sentiment score of 1.12 beat Chemed's score of 0.57 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Chemed
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

West Pharmaceutical Services pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Chemed pays an annual dividend of $2.80 per share and has a dividend yield of 0.5%. West Pharmaceutical Services pays out 11.7% of its earnings in the form of a dividend. Chemed pays out 13.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has raised its dividend for 16 consecutive years. Chemed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

West Pharmaceutical Services has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B9.43$493.70M$8.9146.73
Chemed$2.53B2.83$265.24M$20.9026.28

West Pharmaceutical Services has a net margin of 18.81% compared to Chemed's net margin of 10.61%. Chemed's return on equity of 35.18% beat West Pharmaceutical Services' return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services18.81% 21.78% 15.99%
Chemed 10.61%35.18%19.43%

Summary

West Pharmaceutical Services beats Chemed on 11 of the 19 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Encompass Health?

West Pharmaceutical Services (NYSE:WST) and Encompass Health (NYSE:EHC) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Encompass Health has higher revenue and earnings than West Pharmaceutical Services. Encompass Health is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B9.43$493.70M$8.9146.73
Encompass Health$6.34B2.18$566.20M$6.4022.01

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Encompass Health. MarketBeat recorded 10 mentions for West Pharmaceutical Services and 4 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.29 beat West Pharmaceutical Services' score of 1.12 indicating that Encompass Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Encompass Health
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

West Pharmaceutical Services pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Encompass Health pays an annual dividend of $0.84 per share and has a dividend yield of 0.6%. West Pharmaceutical Services pays out 11.7% of its earnings in the form of a dividend. Encompass Health pays out 13.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Encompass Health has increased its dividend for 2 consecutive years. Encompass Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

West Pharmaceutical Services has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Encompass Health has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 97.3% of Encompass Health shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 1.8% of Encompass Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

West Pharmaceutical Services has a net margin of 18.81% compared to Encompass Health's net margin of 10.17%. West Pharmaceutical Services' return on equity of 21.78% beat Encompass Health's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services18.81% 21.78% 15.99%
Encompass Health 10.17%18.35%8.38%

West Pharmaceutical Services presently has a consensus price target of $424.67, indicating a potential upside of 2.00%. Encompass Health has a consensus price target of $154.25, indicating a potential upside of 9.50%. Given Encompass Health's stronger consensus rating and higher possible upside, analysts plainly believe Encompass Health is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
Encompass Health
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

West Pharmaceutical Services and Encompass Health tied by winning 10 of the 20 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Medline?

Medline (NASDAQ:MDLN) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.8% of Medline shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, West Pharmaceutical Services had 2 more articles in the media than Medline. MarketBeat recorded 10 mentions for West Pharmaceutical Services and 8 mentions for Medline. West Pharmaceutical Services' average media sentiment score of 1.12 beat Medline's score of 0.74 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
West Pharmaceutical Services
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Medline presently has a consensus target price of $46.08, suggesting a potential upside of 16.74%. West Pharmaceutical Services has a consensus target price of $424.67, suggesting a potential upside of 2.00%. Given Medline's higher probable upside, analysts plainly believe Medline is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
2 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.72
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93

Medline has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$28.43B1.83$1.16B$0.4489.70
West Pharmaceutical Services$3.07B9.43$493.70M$8.9146.73

West Pharmaceutical Services has a net margin of 18.81% compared to Medline's net margin of 1.84%. West Pharmaceutical Services' return on equity of 21.78% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Medline1.84% 8.21% 4.03%
West Pharmaceutical Services 18.81%21.78%15.99%

Summary

West Pharmaceutical Services beats Medline on 9 of the 15 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Alcon?

West Pharmaceutical Services (NYSE:WST) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

In the previous week, Alcon had 10 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 20 mentions for Alcon and 10 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 1.12 beat Alcon's score of 0.37 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alcon
4 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alcon has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B9.43$493.70M$8.9146.73
Alcon$10.40B3.52$980M$1.3754.06

West Pharmaceutical Services has a net margin of 18.81% compared to Alcon's net margin of 6.06%. West Pharmaceutical Services' return on equity of 21.78% beat Alcon's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services18.81% 21.78% 15.99%
Alcon 6.06%7.54%5.25%

West Pharmaceutical Services currently has a consensus price target of $424.67, suggesting a potential upside of 2.00%. Alcon has a consensus price target of $82.16, suggesting a potential upside of 10.94%. Given Alcon's higher possible upside, analysts plainly believe Alcon is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
Alcon
1 Sell rating(s)
6 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.63

West Pharmaceutical Services has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Alcon has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 53.9% of Alcon shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

West Pharmaceutical Services beats Alcon on 11 of the 17 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Solventum?

Solventum (NYSE:SOLV) and West Pharmaceutical Services (NYSE:WST) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Solventum has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

In the previous week, West Pharmaceutical Services had 8 more articles in the media than Solventum. MarketBeat recorded 10 mentions for West Pharmaceutical Services and 2 mentions for Solventum. West Pharmaceutical Services' average media sentiment score of 1.12 beat Solventum's score of 0.86 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solventum
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
West Pharmaceutical Services
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Solventum currently has a consensus target price of $90.27, indicating a potential upside of 1.60%. West Pharmaceutical Services has a consensus target price of $424.67, indicating a potential upside of 2.00%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solventum
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.71
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93

West Pharmaceutical Services has a net margin of 18.81% compared to Solventum's net margin of 1.91%. Solventum's return on equity of 25.03% beat West Pharmaceutical Services' return on equity.

Company Net Margins Return on Equity Return on Assets
Solventum1.91% 25.03% 8.65%
West Pharmaceutical Services 18.81%21.78%15.99%

Solventum has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solventum$8.33B1.81$1.56B$0.8999.83
West Pharmaceutical Services$3.07B9.43$493.70M$8.9146.73

Summary

West Pharmaceutical Services beats Solventum on 12 of the 17 factors compared between the two stocks.

Get West Pharmaceutical Services News Delivered to You Automatically

Sign up to receive the latest news and ratings for WST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WST vs. The Competition

MetricWest Pharmaceutical ServicesHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$29.06B$5.97B$7.83B$23.17B
Dividend Yield0.25%1.69%2.47%3.79%
P/E Ratio46.8239.0934.3429.41
Price / Sales8.564.848.003.27
Price / Cash42.7624.1821.0215.64
Price / Book9.464.954.764.04
Net Income$493.70M$143.12M$3.52B$1.07B
7 Day Performance0.95%-4.86%-5.34%-3.09%
1 Month Performance8.71%-2.87%-3.61%-1.21%
1 Year Performance59.86%-0.76%0.01%5.63%

West Pharmaceutical Services Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WST
West Pharmaceutical Services
3.9421 of 5 stars
$417.21
+0.2%
$424.67
+1.8%
+59.5%$29.06B$3.40B46.8210,800
CHE
Chemed
3.5712 of 5 stars
$538.84
+2.0%
$603.00
+11.9%
+26.2%$7.14B$2.53B23.9515,811
EHC
Encompass Health
4.0495 of 5 stars
$140.79
+2.4%
$154.25
+9.6%
+24.1%$13.84B$5.94B22.0042,000
MDLN
Medline
3.2028 of 5 stars
$40.71
+2.7%
$46.08
+13.2%
N/A$53.05B$28.43B33.3545,000
ALC
Alcon
2.9665 of 5 stars
$75.20
+0.4%
$82.89
+10.2%
-4.5%$38.24B$10.40B23.7225,942

Related Companies and Tools


This page (NYSE:WST) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners